The purpose of this study is to compare a usual maintenance treatment for multiple myeloma (lenalidomide) to using the study drug (daratumumab/rHuPH20) plus the usual treatment. We want to learn if the addition of daratumumab/rHuPH20 to the usual treatment could help you live longer after your stem cell transplant. This study will help the study doctors find out if this different approach is better than the usual approach.

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Have you been diagnosed with pancreatic cancer? If so, you may be able to take part in a research study looking at the efficacy of neoadjuvant FOLFIRINOX in subjects with non-metastatic pancreatic cancer.

Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.

Have you been diagnosed with B-Cell Lymphoma? Are you looking for options to treat your cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called iC9-CAR19 with Rimiducid.

Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

To determine if treatment with mFOLFOX6/bevacizumab plus atezolizumab ) and atezolizumab is more effective than treatment with mFOLFOX6/bevacizumab alone in patients with metastatic colon cancer.

Do you have lymphoma that has come back, or did not get better with the last treatment you were given? If so, you might able to participate in a study to see if the study team can make modified T cells that are able to fight and kill the lymphoma cells.